Zhengye Biotechnology GAAP EPS of -$0.06, revenue of $7.51M
Zhengye Biotechnology reported a GAAP EPS of -$0.06 and revenue of $7.51M for the first half of the year, according to the company's press release.
Zhengye Biotechnology Holding Ltd
Zhengye Biotechnology, through its operating entity Jilin Zhengye, researches, develops, manufactures and sells veterinary vaccines, with an emphasis on livestock. Its portfolio includes vaccines for swine, cattle, goats, sheep, poultry and dogs, including monovalent, polyvalent and combined vaccines. The operating entity also has a rabies vaccine for dogs and is developing vaccines for household animals. Its products are sold under its own brand through domestic and exporting distributors. Zhengye Biotechnology makes money by manufacturing and selling veterinary vaccines in China and internationally. Its products are available in 29 provincial regions across China and are exported to Vietnam, Pakistan and Egypt. The operating entity has three veterinary vaccine production floors, 13 vaccine production lines, a quality examination center and an animal facility for vaccine development. Its principal executive offices are in Jilin Economic & Technical Development Zone, Jilin Province, China.
No SEC Form 4 filings for $ZYBT in the last 30 days.
See all $ZYBT insider activity →Zhengye Biotechnology reported a GAAP EPS of -$0.06 and revenue of $7.51M for the first half of the year, according to the company's press release.
Zhengye Biotechnology (ZYBT) reported its H1 2026 financial results, showing a net revenue decline of 18.3% to RMB50.9 million (US$7.5 million) and a gross profit decrease of 13.8% to RMB16.7 million (US$2.5 million). Despite these declines, the company improved its gross profit margin by 1.8 percentage points to 32.9%. Operating expenses decreased by 22.2% to RMB37.6 million, and the net loss narrowed by 13.3% to RMB22.2 million (US$3.3 million).
U.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ZYBT (Zhengye Biotechnology Holding Ltd). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent ZYBT coverage spans earnings, market movers and financial news.
Earnings miss with a loss and modest revenue likely pressures the stock.
Revenue drop and lower loss may pressure the stock, though improved gross margin offers some support.
Strong upside momentum is evident, but the article lacks the reason for the jump.
Compliance restores investor confidence and avoids delisting risk.
Regaining bid-price compliance reduces delisting risk, which can stabilize sentiment and lower near-term liquidity/financing concerns.
AlphAI scores every news story that mentions ZYBT with an AI model for sentiment and relevance, and aggregates insider trades from Zhengye Biotechnology Holding Ltd's SEC EDGAR Form 4 filings. Figures refresh continuously.
Zhengye Biotechnology reported a GAAP EPS of -$0.06 and revenue of $7.51M for the first half of the year, according to the company's press release.
Zhengye Biotechnology (ZYBT) reported its H1 2026 financial results, showing a net revenue decline of 18.3% to RMB50.9 million (US$7.5 million) and a gross profit decrease of 13.8% to RMB16.7 million (US$2.5 million). Despite these declines, the company improved its gross profit margin by 1.8 percentage points to 32.9%. Operating expenses decreased by 22.2% to RMB37.6 million, and the net loss narrowed by 13.3% to RMB22.2 million (US$3.3 million).
U.S. stocks closed higher on Friday, with the Dow Jones up 0.83%, S&P 500 up 0.59%, and Nasdaq up 0.64%. Top performers included Amazon, Cisco, and Visa, while Verizon, 3M, and Home Depot declined. Moderna and Crown Castle also saw significant gains. Oil prices fell slightly, and gold futures rose. The CBOE Volatility Index decreased by 3.70%.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) said Nasdaq notified it on Aug. 5, 2026 that it regained compliance with the $1.00 minimum bid price requirement under Nasdaq Rule 5550(a)(2). Nasdaq previously flagged ZYBT for trading below $1.00 for 30 straight business days, but determined the bid was at or above $1.00 for the last 10 consecutive sessions from July 20 to Aug. 4.
Biotech gainers included Zhengye Biotechnology (ZYBT), up about 1,048% after a Nasdaq bid-price noncompliance notice. Advanced Biomed (ADVB) rose over 70% after withdrawing a planned SEC-registered offering. Neuronetics (STIM) gained after naming a new CFO. Armata Pharmaceuticals (ARMP) advanced on Phase 3 AP-SA02 progress. Other movers: Profusa (PFSA), Ridgetech (RDGT), Turn Therapeutics (TTRX).
Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get access to the leaderboards pointing to tomorrow's biggest stock movers.
Jilin, China, May 23, 2025 ( GLOBE NEWSWIRE ) -- Zhengye Biotechnology Holding Limited ( Nasdaq: ZYBT ) ( the "Company" or "Zhengye" ) , a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines ...